新型藥物植入物為糖尿病患者提供每週注射以外的新選擇
New Drug Implants Offer Alternative to Weekly Injections for Diabetes
Updated at: June 24, 2026 at 08:15 AM
對於數百萬名糖尿病患者而言，每日或每週的注射是一項沈重的負擔，往往導致血糖控制不穩定及身體不適。
For millions living with diabetes, daily or weekly injections are a significant burden, often leading to inconsistent blood sugar control and physical discomfort.
近期，醫學研究人員將目光轉向植入式藥物輸送系統（Implantable Drug Delivery Systems，簡稱 IDDS）作為一種革命性的替代方案。
Recently, medical researchers have turned their attention to Implantable Drug Delivery Systems (IDDS) as a revolutionary alternative.
這些植入裝置旨在數週或數月內穩定釋放藥物，確保血液中的治療藥物濃度維持恆定。
These implants are designed to release medication steadily over weeks or months, ensuring consistent therapeutic levels in the bloodstream.
無論是透過生物可降解聚合物、可編程幫浦，還是尖端的封裝胰島細胞，這些裝置的目標都是免除頻繁給藥的需求。
Whether through biodegradable polymers, programmable pumps, or cutting-edge encapsulated islet cells, these devices aim to eliminate the need for frequent dosing.
其優點顯而易見：透過自動化輸送，植入裝置能提高患者的治療依從性，降低危險的血糖波動風險，並最大限度地減少與全身性藥物暴露相關的副作用。
The benefits are clear: by automating delivery, implants improve treatment adherence, reduce the risk of dangerous glucose fluctuations, and minimize the side effects associated with systemic drug exposure.
儘管目前面臨長期裝置穩定性與免疫排斥的問題，但包括自我調節胰島細胞在內的相關研究正迅速取得進展。
While currently facing challenges regarding long-term device stability and immune rejection, the research—including promising studies on self-regulating islet cells—is rapidly advancing.
透過將植入裝置與人工智慧及穿戴式感測器結合，糖尿病管理的未來正變得日益自動化。
By integrating implants with AI and wearable sensors, the future of diabetes management looks increasingly automated.
這種轉變代表了一種跨越，即從每日面對注射的掙扎，轉向更被動、長期的解決方案，為患者提供更高的生活品質，也是個人化自動化醫學邁出的重要一步。
This shift represents a transition from the daily struggle of reactive injections to a more passive, long-term solution, offering patients a higher quality of life and a significant step forward in personalized, automated medicine.
